Thanks, Mr. Chair.
Thank you to the witnesses for coming here today.
I found it interesting that the Canadian Diabetes Association recommended an independent review. We've heard that. It seems to be a recurring theme here at the committee, and I'm sure the researchers are taking note of that.
I have a few questions. This is a very complicated issue and I only have five minutes.
One question that keeps coming up is having national standards. Madam Bennett suggested coordinating all the different plans. I wonder what the safeguard would be to preventing all the drug plans from going to the lowest common denominator versus the highest common denominator, and once you had established a highest common denominator over time, it would seem to be a lot more difficult to change the bar if you made it somehow compulsory for all the participants to agree on a certain standard. If a province, for example, wanted to exceed the standard, it would be very difficult for it to do so.
I'd like a comment on that.
This is the second question. I'd like the Canadian Diabetes Association to elaborate a little bit more on the proposal for conditional listing. It sounds like you want to replace the recommendations not to list with conditional listing recommendations. Would that not entail a lot more process at the level of the provinces, which then have to adjudicate each request on a case-by-case basis?
Finally, maybe for the Fraser Institute, if you had your wish, what is the cost estimate? You've said the CDR uses cost as a major consideration. If we removed that, what dollar figures are we actually talking about?
Those are my questions, Mr. Chair.